Table 2.
Comparison of demographic and clinical characteristics between SLE patients with and without miR-98 low expression.
| Patients with miR-98 low expression (n = 21) | Patients without miR-98 low expression∗ (n = 20) | p | |
|---|---|---|---|
| Female, n (%) | 17 (81.0) | 20 (100.0) | 0.126 |
| Age at SLE diagnosis, yrs, mean ± SD | 34.27 ± 20.25 | 30.54 ± 7.37 | 0.606 |
| Skin rash, n (%) | 6 (28.6) | 10 (50.0) | 0.160 |
| Oral ulcer, n (%) | 7 (33.3) | 9 (45.0) | 0.401 |
| Arthritis, n (%)∗∗ | 16 (28.6) | 10 (50.0) | 0.001 |
| Polyserositis, n (%) | 4 (19.0) | 3 (15.0) | 0.732 |
| Lupus nephritis, n (%)∗∗ | 14(66.7) | 6 (30.0) | 0.019 |
| Central nervous system involvement, n (%) | 4 (19.0) | 2 (10.0) | 0.706 |
| SCr (μmol/L), mean ± SD | 121.80 ± 81.19 | 98.46 ± 63.64 | 0.093 |
| ALB (g/L), mean ± SD | 26.71 ± 6.32 | 28.42 ± 5.25 | 0.120 |
| Complement 3 (g/L), mean ± SD | 0.37 ± 0.14 | 0.44 ± 0.26 | 0.133 |
| IgG (g/L), mean ± SD | 12.72 ± 5.63 | 16.01 ± 6.68 | 0.154 |
| ACL (IgM/IgG), n (%) | 1 (4.8) | 1 (5.0) | 0.938 |
| Anti-β2-GP1 (IgG), n (%) | 2 (9.5) | 1 (5.0) | 0.720 |
| ANA, n (%) | 19 (90.5) | 19 (95.0) | 0.593 |
| Anti-ds-DNA, n (%)∗∗ | 13 (61.9) | 3 (15.0) | 0.004 |
| Anti-Sm, n (%) | 4 (19.0) | 0 (0.0) | 0.107 |
| Anti-Ro, n (%) | 12 (57.1) | 7 (35.0) | 0.105 |
| Anti-La, n (%) | 3 (14.3) | 1 (5.0) | 0.606 |
| Anti-U1RNP, n (%) | 4 (19.0) | 2 (10.0) | 0.663 |
| Corticosteroid therapy, n (%) | 21 (100.0) | 19 (95.0) | 0.773 |
| IV CYC therapy, n (%) | 14 (66.7) | 9(45.0) | 0.577 |
| MMF therapy, n (%) | 3 (14.3) | 2 (10.0) | 0.682 |
| Hydroxychloroquine therapy, n (%) | 19 (90.5) | 19 (95.0) | 0.593 |
| Disease activity (SLEDAI, mean ± SD)∗∗ | 14.93 ± 7.91 | 7.13 ± 6.68 | 0.032 |
∗Patients with normal and overexpression of miR-98; ∗∗p value < 0.5.